SkinBioTherapeutics PLC health authority approval for AxisBiotix in France (6038M)
15 Septiembre 2023 - 3:00AM
UK Regulatory
TIDMSBTX
RNS Number : 6038M
SkinBioTherapeutics PLC
15 September 2023
SkinBioTherapeutics plc
("SkinBioTherapeutics" or "the Company")
AxisBiotix-Ps(TM) receives health authority approval for launch
in France
-- Third European market to receive approval after Spain and Italy earlier in 2023
-- Marketing to customers to start in October 2023
-- Additional new geographical revenue stream
15 September 2023 - SkinBioTherapeutics plc (AIM: SBTX), a life
science business focused on skin health, has announced that it has
received approval from regulators to sell AxisBiotix-Ps(TM), a food
supplement to alleviate the symptoms associated with Psoriasis,
into the French market. Marketing of the product is expected to
launch in France in October.
The announcement follows the launch of AxisBiotix-Ps(TM) in
Spain and Italy earlier this year, after prior authorisation was
received in March and June respectively. Building on the initial
launch in the UK where customer retention rates have remained above
80%,(1) the launch of AxisBiotix-Ps into another European market is
the continuation of this commercialisation strategy.
Psoriasis is a common skin condition that effects 2-3% of the
global population. There are as many as 2 million people suffering
from psoriasis in France. Like other Western European countries,
France has high rates of food supplement use, with one-third of
respondents to a recent survey indicating they regularly use such
supplements, and over half saying they had used them in the past
year.(2)
The next target country for launch is to be confirmed, but the
Company is in talks with other European regulatory agencies to
expand the availability of AxisBiotix-Ps(TM) .
Stuart J. Ashman, CEO of SkinBioTherapeutics, said: "In line
with our strategic plan, we are delighted that AxisBiotix-Ps(TM) is
now approved for sale in another market, after the previous
launches in the UK, Spain, and Italy. We anticipate an open
reception from potential new customers in our European markets due
to their positive attitude to food supplements. We have now
completed the goal of launching in three major European markets in
2023 and we look forward to updating the market on other country
launches next year."
Psoriasis is a lifelong condition, with no known cure, which
impacts the everyday lives of sufferers. Existing treatments such
as steroids or immuno-suppressants cannot be used over the
long-term, which makes AxisBiotix-Ps (TM) an effective solution to
alleviate its symptoms. As a food supplement, AxisBiotix-Ps(TM) is
a food supplement that seeks to act on the gut-skin axis
re-introducing missing bacteria into the gut and redressing the
balance to improve skin health. The importance of the gut-skin axis
is backed by strong scientific data.
1: Retention rates being measured as the number of subscribers
who are remaining as a subscriber at the end of each month,
compared to the same cohort that were in existence at the start of
the previous month.
2: 'Baromètre 2022 de la consommation des compléments
alimentaires en France', Synadiet, 10 March 2022,
https://www.synadiet.org/app/uploads/2022/04/202111060_harris_interactive_rapport_barometre_conso_cpal_2022_v2.pdf
Change of Name of Nominated Adviser and Broker
The Company also announces that its Nominated Adviser and Sole
Broker has changed its name to Cavendish Securities plc following
completion of its own corporate merger.
-Ends-
The information communicated in this announcement contains
inside information for the purposes of Article 7 of the Market
Abuse Regulation (EU) No. 596/2014.
For more information please contact:
SkinBioTherapeutics plc Tel: +44 (0) 191
Stuart J . Ashman, CEO 495 7325
Manprit Randhawa, CFO
Cavendish Securities Plc (Nominated Adviser Tel: +44 (0) 207
& Broker) 220 0500
Giles Balleny, Charlie Combe (Corporate
Finance)
Dale Bellis, Tamar Cranford-Smith (Sales)
Instinctif Partners (financial press) Tel: +44 (0) 20 7457
Melanie Toyne-Sewell / Tim Field / Adam 2020
Loudon SkinBioT herapeutics@instinctif.com
Notes to Editors
About SkinBioTherapeutics plc
SkinBioTherapeutics is a life science company focused on skin
health. The Company's proprietary platform technology,
SkinBiotix(R), is based upon discoveries made by Professor
Catherine O'Neill and Professor Andrew McBain.
The Company is targeting a number of skin healthcare sectors,
the most advanced of which are cosmetic skincare and food
supplements to modulate the immune system by harnessing the
gut-skin axis. In each area SkinBioTherapeutics plans to exemplify
its technology through human studies. The Company's first product,
AxisBiotix-Ps(TM), a food supplement to address the symptoms of
mild to moderate psoriasis.
The Company listed on AIM in April 2017 and is based in
Newcastle, UK.
For more information, visit: www.skinbiotix.com and
www.axisbiotix.com .
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCEAXNSFLADEEA
(END) Dow Jones Newswires
September 15, 2023 04:00 ET (08:00 GMT)
Skinbiotherapeutics (LSE:SBTX)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
Skinbiotherapeutics (LSE:SBTX)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024
